Achillion Pharmaceuticals

Pipeline

ACH-3422

ACH-3422 is a novel nucleotide NS5B polymerase inhibitor, which was found to be safe and well tolerated in a proof-of-concept trial and demonstrated a 4.2 log10 reduction in viral load with the 700 mg dose after 14 days of treatment.